Abstract

Rotovirus infection (RVI) caused by the dsRNA-containing virus from genus Rotavirus, Reoviridae family, belonging to group A (RVA), is the cause of severe diarrhea in human and other mammalian species. Vaccination is the most effective way to reduce the incidence of RVI. At present, the effectiveness of using gnotobiotic piglets as a universal model for reproducing human rotavirus infection and assessing the quality of RVI vaccine preparations has been experimentally proven. Evaluation of immunogenic activity of the cloned RVA Wa strain in the new-born Vietnamese potbellied piglets trial. Development of viral preparations of the cloned human Wa strain PBA, development of human RVA rVP6, ELISA, polymerase chain reaction with reverse transcription, immunization and experimental infection of newborn piglets. The article presents the results of the experiment on double immunization of newborn piglets with native virus preparations with the infection activity 5.5 lg TCID50/ml, 3 cm3 per dose, HRV with adjuvant 500 µg per dose and mock preparation (control group) followed with experimental inoculation of all animals with virulent virus strain Wa G1P[8] human RVA with infectious activity of 5.5 lg TCID50/ml in 5 cm3 dose. Development of clinical signs of disease and animal death were observed only in control group. RT-PCR system to detect RVA RNA in rectal swabs, samples of small intestine and peripheral lymph nodes was developed. ELISA based on obtained human RVA rVP6 was developed and results on RVA-specific IgG-antibodies in serum samples of experimental piglets are presented. In the course of the research, a high immunogenic activity of the native and purified virus of the cloned Wa RVA strain Wa was established and the possibility of its use as the main component of the RVI vaccine was confirmed. The possibility of using conventional newborn pigs instead of gnotobiotic piglets as an experimental model was demonstrated.

Highlights

  • Rotovirus infection (RVI) caused by the dsRNA-containing virus from genus Rotavirus, Reoviridae family, belonging to group A (RVA), is the cause of severe diarrhea in human and other mammalian species

  • Vaccination is the most effective way to reduce the incidence of RVI

  • The article presents the results of the experiment on double immunization of newborn piglets with native virus preparations with the infection activity 5.5 lg TCID50/ml, 3 cm3 per dose, HRV with adjuvant 500 μg per dose and mock preparation followed with experimental inoculation of all animals with virulent virus strain Wa G1P[8] human RVA with infectious activity of 5.5 lg TCID50/ml in 5 cm3 dose

Read more

Summary

ОЦЕНКА ИММУНОГЕННОЙ АКТИВНОСТИ КЛОНИРОВАННОГО ШТАММА WA РОТАВИРУСА А ЧЕЛОВЕКА

Иммуноферментный анализ и полимеразная цепная реакция с обратной транскрипцией для выявления РВА человека. В статье представлены результаты опыта по двукратной иммунизации новорождённых поросят препаратами нативного вируса с инфекционной активностью 5,5 lg ТЦИД50/мл в дозе 3 см, HRV с адъювантом в дозе 500 мкг и плацебо (контроль) с последующим экспериментальным заражением всех животных вирусом вирулентного штамма Wa G1P[8] РВА человека с инфекционной активностью 5,5 lg ТЦИД50/мл в дозе 5 см. На основе полученного rVP6 РВА человека разработан метод выявления специфических IgG-антител к РВА с помощью иммуноферментного анализа (ИФА), и приведены результаты выявления РВА в сыворотке крови подопытных поросят. В ходе проведённых исследований установлена высокая иммуногенная активность нативного и очищенного вируса клонированного штамма Wa РВА и подтверждена возможность его применения в качестве основного компонента вакцины против РВИ. Ключевые слова: ротавирус А; рекомбинантный белок VP6; иммунизация; заражение; ОТ-ПЦР; иммуноферментный анализ; новорожденные поросята

Introduction
Материал и методы
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call